MedTrace Logo

S-33 SMR Shoulder HP Reverse Glenosphere

NCT05339815 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 140

Last updated 2022-10-24

No results posted yet for this study

Summary

Study Design: Single arm, retrospective and prospective, single center, post-market clinical study Purpose:To demonstrate the safety and effectiveness of the SMR Reverse HP Shoulder System device for primary, fracture or revision total shoulder replacement out to 24 months. The eligible study population is the entire population that underwent a reverse shoulder arthroplasty performed with 36-mm CoCrMo versus 40-mm cross-linked UHMWPE glenospheres between January 1, 2013 and January 1, 2020 at Wrightington Hospital (UK) in accordance with the indication for use of the product.

Conditions

  • Arthroplasty, Replacement, Shoulder

Interventions

DEVICE

SMR shoulder arthroplasty

Data collection of population that underwent a reverse shoulder arthroplasty performed with SMR 36-mm CoCrMo versus 40-mm cross-linked UHMWPE glenospheres

Sponsors & Collaborators

  • Limacorporate S.p.a

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-17
Primary Completion
2023-02-28
Completion
2023-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05339815 on ClinicalTrials.gov